Type 2 diabetes mellitus increases the mortality risk after acute coronary syndrome treated with coronary artery bypass surgery.
Acute Coronary Syndrome
/ diagnostic imaging
Aged
Cause of Death
Comorbidity
Coronary Artery Bypass
/ adverse effects
Diabetes Mellitus, Type 2
/ diagnosis
Diet, Diabetic
Female
Humans
Hypoglycemic Agents
/ therapeutic use
Israel
/ epidemiology
Male
Middle Aged
Prospective Studies
Recurrence
Registries
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Coronary artery bypass grafting
Diabetes mellitus
Insulin
Revascularization
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
13 06 2020
13 06 2020
Historique:
received:
09
04
2020
accepted:
08
06
2020
entrez:
15
6
2020
pubmed:
15
6
2020
medline:
4
11
2020
Statut:
epublish
Résumé
Type 2 diabetes mellitus (DM) is a risk factor for cardiovascular diseases and is common among patients undergoing coronary artery bypass grafting (CABG) surgery. The main objective of our study was to investigate the impact of DM type 2, and its treatment subgroups, on short- and long-term mortality in patients with acute coronary syndrome (ACS) who undergo CABG. The study included 1307 patients enrolled from the biennial Acute Coronary Syndrome Israeli Survey between 2000 and 2016, who were hospitalized for ACS and underwent CABG. Of them, 527 (40%) patients were with and 780 (60%) were without DM. Compared with the non-diabetic group, the diabetic group of patients comprised more women and had more comorbidities such as hypertension, dyslipidemia, renal impairment, peripheral vascular disease and prior ischemic heart disease. Overall 30-day mortality rate was similar between DM and non-DM patients (4.2% vs. 4%, p = 0.976). Ten-year mortality rate was higher in DM compared with non-diabetic patients (26.6% vs. 17.7%, log-rank p < 0.001), and higher in the subgroup of insulin-treated patients compared to non-insulin treated patients (31.5% vs. 25.6%, log-rank p = 0.019). Multivariable analysis showed that DM increased the mortality hazard by 1.61-fold, and insulin treatment among the diabetic patients increased the mortality hazard by 1.57-fold. While type 2 DM did not influence the in-hospital mortality hazard, we showed that the presence of DM among patients with ACS referred to CABG, is a powerful risk factor for long-term mortality, especially when insulin was included in the diabetic treatment strategy.
Sections du résumé
BACKGROUND
Type 2 diabetes mellitus (DM) is a risk factor for cardiovascular diseases and is common among patients undergoing coronary artery bypass grafting (CABG) surgery. The main objective of our study was to investigate the impact of DM type 2, and its treatment subgroups, on short- and long-term mortality in patients with acute coronary syndrome (ACS) who undergo CABG.
METHODS
The study included 1307 patients enrolled from the biennial Acute Coronary Syndrome Israeli Survey between 2000 and 2016, who were hospitalized for ACS and underwent CABG. Of them, 527 (40%) patients were with and 780 (60%) were without DM.
RESULTS
Compared with the non-diabetic group, the diabetic group of patients comprised more women and had more comorbidities such as hypertension, dyslipidemia, renal impairment, peripheral vascular disease and prior ischemic heart disease. Overall 30-day mortality rate was similar between DM and non-DM patients (4.2% vs. 4%, p = 0.976). Ten-year mortality rate was higher in DM compared with non-diabetic patients (26.6% vs. 17.7%, log-rank p < 0.001), and higher in the subgroup of insulin-treated patients compared to non-insulin treated patients (31.5% vs. 25.6%, log-rank p = 0.019). Multivariable analysis showed that DM increased the mortality hazard by 1.61-fold, and insulin treatment among the diabetic patients increased the mortality hazard by 1.57-fold.
CONCLUSIONS
While type 2 DM did not influence the in-hospital mortality hazard, we showed that the presence of DM among patients with ACS referred to CABG, is a powerful risk factor for long-term mortality, especially when insulin was included in the diabetic treatment strategy.
Identifiants
pubmed: 32534591
doi: 10.1186/s12933-020-01069-6
pii: 10.1186/s12933-020-01069-6
pmc: PMC7293781
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Références
Am Heart J. 2015 Jan;169(1):175-84
pubmed: 25497264
J Am Coll Cardiol. 2002 Aug 7;40(3):418-23
pubmed: 12142105
Eur J Cardiothorac Surg. 2013 May;43(5):1006-13
pubmed: 23413014
Ann Thorac Surg. 2020 Mar 19;:
pubmed: 32199825
Acta Diabetol. 2013 Apr;50(2):123-8
pubmed: 20857149
Circulation. 2014 Jun 17;129(24):2518-27
pubmed: 24787469
Circulation. 2001 Jul 31;104(5):533-8
pubmed: 11479249
Cardiovasc Diabetol. 2018 Nov 29;17(1):151
pubmed: 30497472
Cardiovasc Diabetol. 2019 Mar 15;18(1):31
pubmed: 30876424
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Circulation. 2014 Dec 23;130(25):2354-94
pubmed: 25249586
Cardiovasc Diabetol. 2019 Oct 8;18(1):131
pubmed: 31594547
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
JACC Cardiovasc Interv. 2011 Mar;4(3):317-23
pubmed: 21435610
Eur Heart J. 2004 Nov;25(21):1891-7
pubmed: 15522467
Am J Cardiol. 2015 Apr 15;115(8):1063-72
pubmed: 25733384
Catheter Cardiovasc Interv. 2011 Oct 1;78(4):537-9
pubmed: 21953750
Trends Cardiovasc Med. 2016 Feb;26(2):165-79
pubmed: 26411567
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Can J Cardiol. 2018 May;34(5):632-643
pubmed: 29731023
Ann Thorac Surg. 2015 Dec;100(6):2262-9
pubmed: 26319487
Clin Cardiol. 2014 Oct;37(10):605-9
pubmed: 25269657
Isr Med Assoc J. 2003 Apr;5(4):249-54
pubmed: 14509128